Benzinga | Nov 24, 2021 07:39AM EST

Oppenheimer Maintains Perform on Enanta Pharmaceuticals, Raises Price Target to $73

Oppenheimer analyst Jay Olson maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Perform and raises the price target from $55 to $73.